Immune study of hereditary pheochromocytoma tumors
Part of Cancer clinical trials.
This study looks at how the immune system responds to rare adrenal or nerve-related tumors (pheochromocytoma and paraganglioma). Researchers want to understand the tumor's environment, which may help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been newly diagnosed with pheochromocytoma or paraganglioma (PPGL), or have had a recurrence of metastatic PPGL.
- Or you have a genetic mutation that puts you at high risk for these tumors.
- Your tumor has been confirmed by a pathology report (for Part II of the study).
- You do not have an active infection or inflammatory condition.
- You are not currently receiving treatment for another cancer (except certain skin or early-stage cancers).
- You are not taking immune-suppressing medications, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.
This study helps doctors better understand and diagnose pheochromocytoma and paraganglioma—rare tumors that release stress hormones and cause high blood pressure and other symptoms. Researchers will study your medical history, blood and urine tests, imaging scans, and genetic information to improve how these conditions are found and understood.
This study looks at genetic (DNA) changes in people with pheochromocytoma or paraganglioma and related conditions. It may help clarify why these conditions happen and how they run in families.
This study looks at past patient data to find patterns that might predict whether a pheochromocytoma or paraganglioma (rare tumors of the adrenal glands or nerve tissue) will spread. It aims to create a tool to help doctors estimate risk and plan treatment.
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
This trial tests two targeted drugs, anlotinib and benmelstobart, for people with advanced pheochromocytoma or paraganglioma that has spread or come back after treatment. These drugs may help shrink tumors or slow their growth.
Hear when a new Pheochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.